Immune Design Corp.
GLA monotherapy for use in cancer treatment

Last updated:

Abstract:

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.

Status:
Grant
Type:

Utility

Filling date:

20 May 2019

Issue date:

4 May 2021